Sustained remission of CIDP associated with Evans syndrome

被引：42

作者：

Knecht, H ^{[1
]}

Baumberger, M

Tobòn, A

Steck, A

机构：

[1] Swiss Parapleg Ctr, Inst Clin Res, CH-6207 Luzern, Switzerland

[2] Swiss Parapleg Ctr, Med Clin, CH-6207 Luzern, Switzerland

[3] Univ Hosp, Dept Neurol, Basel, Switzerland

来源：

NEUROLOGY | 2004年 / 63卷 / 04期

关键词：

D O I：

10.1212/01.WNL.0000134606.50529.C7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A patient with chronic inflammatory demyelinating polyneuropathy (CIDP) developed Evans syndrome (hemolytic anemia/thrombocytopenia) 17 months after onset of symptoms despite different immunomodulatory treatments. A therapeutic approach with the chimeric monoclonal anti-CD20 antibody rituximab induced substantial improvement of CIDP and hematologic recovery. The patient remains in sustained remission 17 months after completion of therapy. Rituximab may represent a successful therapy in otherwise refractory CIDP.

引用

页码：730 / 732

页数：3

共 10 条

[1] PRIMARY THROMBOCYTOPENIC PURPURA AND ACQUIRED HEMOLYTIC ANEMIA - EVIDENCE FOR A COMMON ETIOLOGY [J].

EVANS, RS ;

TAKAHASHI, K ;

DUANE, RT ;

PAYNE, R ;

LIU, CK .

ARCHIVES OF INTERNAL MEDICINE, 1951, 87 (01) :48-65

[2] Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy [J].

Hughes, R ;

Bensa, S ;

Willison, H ;

Van den Bergh, P ;

Comi, G ;

Illa, I ;

Nobile-Orazio, E ;

van Doorn, P ;

Dalakas, M ;

Bojar, M ;

Swan, A .

ANNALS OF NEUROLOGY, 2001, 50 (02) :195-201

[3] Management of chronic inflammatory demyelinating polyradiculoneuropathy [J].

Hughes, RAC .

DRUGS, 2003, 63 (03) :275-287

[4]

KIPPS TJ, 1993, BLOOD, V81, P2475

[5] Therapy of CIDP and related immunemediated neuropathies [J].

Koski, CL .

NEUROLOGY, 2002, 59 (12) :S22-S27

[6] Diagnosis of CIDP [J].

Latov, N .

NEUROLOGY, 2002, 59 (12) :S2-S6

[7] Rituximab: perspective on single agent experience, and future directions in combination trials [J].

McLaughlin, P .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (01) :3-16

[8] Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies [J].

Renaud, S ;

Gregor, M ;

Fuhr, P ;

Lorenz, D ;

Deuschl, G ;

Gratwohl, A ;

Steck, AJ .

MUSCLE & NERVE, 2003, 27 (05) :611-615

[9] Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome [J].

Seipelt, G ;

Böhme, A ;

Koschmieder, S ;

Hoelzer, D .

ANNALS OF HEMATOLOGY, 2001, 80 (03) :170-173

[10] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura [J].

Stasi, R ;

Pagano, A ;

Stipa, E ;

Amadori, S .

BLOOD, 2001, 98 (04) :952-957

← 1 →